Results 11 to 20 of about 15,094 (231)

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

open access: yesAlzheimer’s Research & Therapy, 2023
Background Rapidly progressive forms of Alzheimer’s disease (rpAD) are increasingly recognized and may have a prevalence of up to 30% of patients among all patients with Alzheimer’s disease (AD).
Janne Marieke Herden   +14 more
doaj   +1 more source

Variant CJD: Reflections a Quarter of a Century on

open access: yesPathogens, 2021
Twenty-five years has now passed since variant Creutzfeldt-Jakob disease (vCJD) was first described in the United Kingdom (UK). Early epidemiological, neuropathological and biochemical investigations suggested that vCJD represented a new zoonotic form of
D. Ritchie, A. Peden, Marcelo A. Barria
semanticscholar   +1 more source

A clinicopathological study of selected cognitive impairment cases in Lothian, Scotland: enhanced CJD surveillance in the 65 + population group

open access: yesBMC Geriatrics, 2022
Background Variant Creutzfeldt-Jakob Disease (vCJD) is primarily associated with dietary exposure to bovine-spongiform-encephalopathy. Cases may be missed in the elderly population where dementia is common with less frequent referral to specialist ...
Lovney Kanguru   +5 more
doaj   +1 more source

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

open access: yesAlzheimer’s Research & Therapy, 2022
Background Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s disease in reactive microglia and
Peter Hermann   +13 more
doaj   +1 more source

Plasma YKL-40 in the spectrum of neurodegenerative dementia

open access: yesJournal of Neuroinflammation, 2019
Background Increased plasma YKL-40 has been reported in Alzheimer’s disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias.
Anna Villar-Piqué   +9 more
doaj   +1 more source

Case report: Two clusters of Creutzfeldt–Jakob disease cases within 1 year in West Michigan

open access: yesFrontiers in Neurology, 2023
BackgroundCreutzfeldt–Jakob disease (CJD) is a rare, rapidly progressive, and uniformly fatal neurodegenerative disease. The reported incidence of CJD is 1 to 2 per million people worldwide annually, with fewer than 1,000 cases in the United States per ...
Ling Ling Rong   +7 more
doaj   +1 more source

Study protocol for enhanced CJD surveillance in the 65+ years population group in Scotland: an observational neuropathological screening study of banked brain tissue donations for evidence of prion disease

open access: yesBMJ Open, 2019
Introduction Creutzfeldt-Jakob disease (CJD) is a human prion disease that occurs in sporadic, genetic and acquired forms. Variant CJD (vCJD) is an acquired form first identified in 1996 in the UK. To date, 178 cases of vCJD have been reported in the UK,
Colin Smith   +4 more
doaj   +1 more source

RT-QuIC: a new test for sporadic CJD

open access: yesPractical Neurology, 2018
The diagnosis of sporadic Creutzfeldt-Jakob disease (CJD) can be difficult, but the real-time quaking-induced conversion (RT-QuIC) assays have made a considerable impact on its clinical diagnosis.
A. Green
semanticscholar   +1 more source

The human spongiform encephalopathies [PDF]

open access: yesRomanian Journal of Neurology, 2018
The human spongiform encephalopathies are a group of heterogenous, usually fatal diseases, characterized by a unique pathogenetic mechanism and distinct clinical presentation. They are classified into sporadic, familial and acquired forms.
Mavroudis Ioannis   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy